期刊文献+
共找到2,510篇文章
< 1 2 126 >
每页显示 20 50 100
曲妥珠单抗联合化疗对HER-2阳性晚期胃癌患者肿瘤标志物及生存质量的影响
1
作者 蒋涛 谢骥 +1 位作者 屈丽娜 于尚睿 《临床合理用药》 2026年第1期12-15,共4页
目的 观察曲妥珠单抗联合化疗对人表皮生长因子受体-2(HER-2)阳性晚期胃癌患者肿瘤标志物及生存质量的影响。方法 选取2021年3月—2024年3月兰州大学第二医院收治的HER-2阳性晚期胃癌患者69例,采用随机数字表法分为观察组(n=35)和对照组... 目的 观察曲妥珠单抗联合化疗对人表皮生长因子受体-2(HER-2)阳性晚期胃癌患者肿瘤标志物及生存质量的影响。方法 选取2021年3月—2024年3月兰州大学第二医院收治的HER-2阳性晚期胃癌患者69例,采用随机数字表法分为观察组(n=35)和对照组(n=34)。观察组给予曲妥珠单抗联合奥沙利铂+替吉奥(SOX方案)治疗,对照组给予SOX方案治疗,每3周为1个周期,2组均治疗2个周期。比较2组近期疗效,治疗前后肿瘤标志物[糖类抗原(CA)125、CA19-9、癌胚抗原(CEA)、甲胎蛋白(AFP)]水平、生存质量[卡氏功能状态(KPS)评分]。结果 观察组客观缓解率为65.71%,高于对照组的41.18%(χ^(2)=4.176,P=0.041)。治疗2个周期后,2组血清CA125、CA19-9、CEA、AFP水平低于治疗前,且观察组低于对照组(P<0.01)。治疗1、2个周期后,2组KPS评分高于治疗前,且观察组高于对照组(P<0.01)。结论 曲妥珠单抗联合化疗治疗HER-2阳性晚期胃癌的效果较好,可显著降低肿瘤标志物水平,提高患者的生存质量。 展开更多
关键词 胃癌 her-2阳性 晚期 曲妥珠单抗 化疗 肿瘤标志物 生存质量
原文传递
多参数MRI影像组学术前预测乳腺癌HER-2表达状态的研究进展
2
作者 关红菲 陈伟彬 《临床医学进展》 2026年第1期1191-1199,共9页
乳腺癌作为全球女性发病率最高的恶性肿瘤,其精准诊疗对改善患者预后至关重要。人表皮生长因子受体2 (Human Epidermal Growth Factor Receptor-2, HER-2)表达状态是乳腺癌精准治疗方案选择的核心依据,传统检测依赖术后病理活检,存在有... 乳腺癌作为全球女性发病率最高的恶性肿瘤,其精准诊疗对改善患者预后至关重要。人表皮生长因子受体2 (Human Epidermal Growth Factor Receptor-2, HER-2)表达状态是乳腺癌精准治疗方案选择的核心依据,传统检测依赖术后病理活检,存在有创性、取样误差及时间滞后等局限。多参数磁共振成像(Multiparametric Magnetic Resonance Imaging, mp-MRI)凭借多序列成像优势,可捕获肿瘤微观病理特征;影像组学技术则能将影像视觉信息转化为高通量量化特征,结合机器学习与深度学习算法,实现肿瘤生物学特征的无创性评估,为术前无创预测HER-2表达提供新路径。本文系统梳理2018~2025年mp-MRI影像组学在乳腺癌HER-2表达预测中的研究进展,从技术流程、序列选择、模型性能、临床价值等方面展开分析,指出当前研究存在的样本量局限、特征重复性不足、临床转化滞后等问题,并提出未来优化方向,为该技术的临床应用与研究深化提供参考。 展开更多
关键词 乳腺癌 her-2 多参数磁共振成像 影像组学 深度学习 术前预测
暂未订购
Drosophila models used to simulate human ATP1A1 gene mutations that cause Charcot-Marie-Tooth type 2 disease and refractory seizures
3
作者 Yao Yuan Lingqi Yu +8 位作者 Xudong Zhuang Dongjing Wen Jin He Jingmei Hong Jiayu Xie Shengan Ling Xiaoyue Du Wenfeng Chen Xinrui Wang 《Neural Regeneration Research》 SCIE CAS 2025年第1期265-276,共12页
Certain amino acids changes in the human Na^(+)/K^(+)-ATPase pump,ATPase Na^(+)/K^(+)transporting subunit alpha 1(ATP1A1),cause Charcot-Marie-Tooth disease type 2(CMT2)disease and refractory seizures.To develop in viv... Certain amino acids changes in the human Na^(+)/K^(+)-ATPase pump,ATPase Na^(+)/K^(+)transporting subunit alpha 1(ATP1A1),cause Charcot-Marie-Tooth disease type 2(CMT2)disease and refractory seizures.To develop in vivo models to study the role of Na^(+)/K^(+)-ATPase in these diseases,we modified the Drosophila gene homolog,Atpα,to mimic the human ATP1A1 gene mutations that cause CMT2.Mutations located within the helical linker region of human ATP1A1(I592T,A597T,P600T,and D601F)were simultaneously introduced into endogenous Drosophila Atpαby CRISPR/Cas9-mediated genome editing,generating the Atpα^(TTTF)model.In addition,the same strategy was used to generate the corresponding single point mutations in flies(Atpα^(I571T),Atpα^(A576T),Atpα^(P579T),and Atpα^(D580F)).Moreover,a deletion mutation(Atpα^(mut))that causes premature termination of translation was generated as a positive control.Of these alleles,we found two that could be maintained as homozygotes(Atpα^(I571T)and Atpα^(P579T)).Three alleles(Atpα^(A576T),Atpα^(P579)and Atpα^(D580F))can form heterozygotes with the Atpαmut allele.We found that the Atpαallele carrying these CMT2-associated mutations showed differential phenotypes in Drosophila.Flies heterozygous for Atpα^(TTTF)mutations have motor performance defects,a reduced lifespan,seizures,and an abnormal neuronal morphology.These Drosophila models will provide a new platform for studying the function and regulation of the sodium-potassium pump. 展开更多
关键词 ATP1A1 Atpα bang-sensitive paralysis Charcot-Marie-Tooth disease type 2 CRISPR/Cas9 homology-directed repair Na^(+)/K^(+)-ATPase point mutation seizures sodium pump
暂未订购
Point mutations of Dicer2 conferred Fusarium asiaticum resistance to RNAi-related biopesticide
4
作者 Kaixin Gu Ran Wei +6 位作者 Yidan Sun Xiaoxin Duan Jing Gao Jianxin Wang Yiping Hou Mingguo Zhou Xiushi Song 《Journal of Integrative Agriculture》 2025年第2期623-637,共15页
The use of RNA interference(RNAi)technology to control pests is explored by researchers globally.Even though RNA is a new class of pest control compound unlike conventional chemical pesticides,the evolution of pest re... The use of RNA interference(RNAi)technology to control pests is explored by researchers globally.Even though RNA is a new class of pest control compound unlike conventional chemical pesticides,the evolution of pest resistance needs to be considered.Here,we first investigate RNAi-based biopesticide resistance of Fusarium asiaticum,which is responsible for devastating diseases of plants,for example,Fusarium head blight.Five resistant strains were isolated from 500 strains that treated with UV-mutagenesis.The mutation common to all of the five resistant mutants occurred in the gene encoding Dicer2(point mutations at codon 1005 and 1007),which were under strong purifying selection pressure.To confirm whether the mutations in Dicer2 confer resistance to RNAi,we exchanged the Dicer2 locus between the sensitive strain and the resistant strain by homologous double exchange.The transformed mutants,Dicer2^(R1005D)and Dicer2^(E1007H),exhibited resistance to dsRNA in vitro.Further study showed that mutations of R1005D and E1007H affected the intramolecular interactions of Dicer2,resulting in the dysfunction of RNase III domain of Dicer2.The amount of sRNAs produced by Dicer2^(R1005D)and Dicer2^(E1007H)was extremely reduced along with variation of sRNA length.Together,these findings revealed a new potential mechanism of RNAi resistance and provided insight into RNAi-related biopesticide deployment for fungal control. 展开更多
关键词 RNA interference DSRNA Dicer2 point mutation RESISTANCE Fusarium asiaticum
在线阅读 下载PDF
Androgen receptor mutations in familial androgen insensitivity syndrome:A metabolic reprogramming pathway to type 2 diabetes susceptibility
5
作者 Cheng Luo Wei-Wei Zhang +9 位作者 Liang-Yan Hua Mei-Qi Zeng Hui Xu Cheng-Zheng Duan Shi-Yu Xu Shuo Zhan Xiao-Fei Pan Da Sun Li-Ya Ye Dong-Juan He 《World Journal of Diabetes》 2025年第11期28-45,共18页
Familial androgen insensitivity syndrome (AIS), resulting from inherited mutations in the androgen receptor (AR)gene, has traditionally been examined within the framework of disorders of sex development. However, grow... Familial androgen insensitivity syndrome (AIS), resulting from inherited mutations in the androgen receptor (AR)gene, has traditionally been examined within the framework of disorders of sex development. However, growingevidence indicates that AR dysfunction also disrupts systemic metabolic homeostasis, predisposing affectedindividuals to insulin resistance and type 2 diabetes mellitus. This article synthesizes recent advances in genetics,transcriptomics, and physiology to elucidate how AR mutations drive tissue-specific metabolic reprogramming inkey organs, including pancreatic β-cells, skeletal muscle, liver, and adipose tissue. Particular attention is given to anewly identified familial AR variant (c.2117A>G;p.Asn706Ser), which not only broadens the known mutationalspectrum of AIS but also underscores the clinical importance of early metabolic risk screening in this population.We further examine how pubertal stage, hormone replacement therapy, and sex-specific signaling pathwaysinteract to influence long-term metabolic outcomes. Lastly, we propose an integrative management framework thatincorporates genetic diagnosis, endocrine surveillance, and personalized pharmacological strategies aimed atreducing the risk of type 2 diabetes mellitus and cardiometabolic complications in individuals with AIS. Distinctfrom previous AIS-centered reviews, this work integrates metabolic and endocrine perspectives into the traditionaldevelopmental paradigm, offering a more comprehensive understanding of disease risk and translational management. 展开更多
关键词 Androgen insensitivity syndrome Androgen receptor Gene mutation Metabolic reprogramming Type 2 diabetes
暂未订购
A barley SS2a single base mutation at the splicing site leads to obvious changes in starch
6
作者 Bang Wang Jing Liu +12 位作者 Xiaolei Chen Qiang Xu Yazhou Zhang Huixue Dong Huaping Tang Pengfei Qi Mei Deng Jian Ma Jirui Wang Guoyue Chen Yuming Wei Youliang Zheng Qiantao Jiang 《Journal of Integrative Agriculture》 2025年第4期1359-1371,共13页
Starch biosynthesis is a complex process that relies on the coordinated action of multiple enzymes.Resistant starch is not digested in the small intestine,thus preventing a rapid rise in the glycemic index.Starch synt... Starch biosynthesis is a complex process that relies on the coordinated action of multiple enzymes.Resistant starch is not digested in the small intestine,thus preventing a rapid rise in the glycemic index.Starch synthase 2a(SS2a)is a key enzyme in amylopectin biosynthesis that has significant effects on starch structure and properties.In this study,we identified an ss2a null mutant(M3-1413)with a single base mutation from an ethyl methane sulfonate(EMS)-mutagenized population of barley.The mutation was located at the 3'end of the first intron of the RNA splicing receptor(AG)site,and resulted in abnormal RNA splicing and two abnormal transcripts of ss2a,which caused the inactivation of the SS2a gene.The starch structure and properties were significantly altered in the mutant,with M3-1413 containing lower total starch and higher amylose and resistant starch levels.This study sheds light on the effect of barley ss2a null mutations on starch properties and will help to guide new applications of barley starch in the development of nutritious food products. 展开更多
关键词 BARLEY EMS mutagenesis starch synthase 2a splicing site mutation starch property resistant starch
在线阅读 下载PDF
The SARS-CoV-2 NSP4 T492I mutation promotes double-membrane vesicle formation to facilitate transmission
7
作者 Pei Wang Buyun Tian +2 位作者 Ke Xiao Wei Ji Zonghong Li 《Virologica Sinica》 2025年第2期225-235,共11页
The evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in mutations not only in the spike protein,aiding immune evasion,but also in the NSP3/4/6 proteins,crucial for regulating double... The evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in mutations not only in the spike protein,aiding immune evasion,but also in the NSP3/4/6 proteins,crucial for regulating double-membrane vesicle(DMV)formation.However,the functional consequences of these NSP3/4/6 mutations remain poorly understood.In this study,a systematic analysis was conducted to investigate the evolutionary patterns of NSP3/4/6 mutations and their impact on DMV formation.The findings revealed that the NSP4 T492I mutation,a prevalent mutation found in all Delta and Omicron sub-lineages,notably enhances DMV formation.Mechanistically,the NSP4 T492I mutation enhances its homodimerization,leading to an increase in the size of puncta induced by NSP3/4,and also augments endoplasmic reticulum(ER)membrane curvature,resulting in a higher DMV density per fluorescent puncta.This study underscores the significance of the NSP4 T492I mutation in modulating DMV formation,with potential implications for the transmission dynamics of SARS-CoV-2.It contributes valuable insights into how these mutations impact viral replication and pathogenesis. 展开更多
关键词 SARS-CoV-2 Virus transmission NSP4 T492I mutation DMV HOMODIMERIZATION ER membrane curvature
原文传递
Dibenzo[a,c]phenazin-11-yl(phenyl)methanone(SBLJ23),a novel selective inhibitor targeting JAK2^(V617F)mutation in myeloproliferative neoplasms
8
作者 MOHAMMAD ABOHASSAN MESFER MOHAMMAD AL SHAHRANI +1 位作者 SARAH KHALED ALOUDA PRASANNA RAJAGOPALAN 《Oncology Research》 2025年第3期675-685,共11页
Background:The JAK2^(V617F)mutation plays a crucial part in the pathogenesis of myeloproliferative neoplasms(MPN),which includes polycythemia vera(PV),essential thrombocythemia(ET),and primary myelofibrosis(PMF)leadin... Background:The JAK2^(V617F)mutation plays a crucial part in the pathogenesis of myeloproliferative neoplasms(MPN),which includes polycythemia vera(PV),essential thrombocythemia(ET),and primary myelofibrosis(PMF)leading to aberrant proliferation and survival of hematopoietic cells.Alongside the challenges of drug resistance and side effects,identifying novel compounds that selectively target JAK2^(V617F)could provide more effective and safer therapeutic options for patients with MPNs.Materials and Methods:We employed computational approaches like high-throughput virtual screening,molecular dynamics simulations(MDS),and binding free energy calculations to identify inhibitors targeting wild and mutant JAK2 kinases.JAK2^(V617F)positive HEL,wild type JAK2 positive TF-1,and non-cancerous Vero cells were used for in vitro validations.Results:SBLJ23 emerged as a top candidate inhibitor with specificity for JAK2^(V617F).Protein-ligand interaction studies and MDS revealed stable interactions and binding of SBLJ23 over the simulation period,with Root Mean Square Deviation(RMSD)indicating consistent binding after 1t15ns.SBLJ23 displayed a half maximal inhibitory concentration(IC_(50))value of 522.4 nM against the JAK2 enzyme.The compound exhibited inhibition of cell proliferation in HEL and TF-1 cells,with half maximal cell growth inhibitory concentration(GI 50)values of 2.51 and 15.87μM,respectively.Moreover,SBLJ23 induced G 2/M cell cycle arrest in HEL cells to facilitate apoptosis in these cell lines.The compound significantly reduced the percentage of phospho JAK2 and phospho STAT3 in HEL cells.Conclusion:High binding affinity,stable interaction profile,favorable binding free energy,and in vitro validations claim SBLJ23 as a potential lead compound against JAK2^(V617F)and suggest further development and optimization towards clinical application in managing myeloproliferative neoplasms. 展开更多
关键词 JAK2^(V617F)mutation Myeloproliferative neoplasms Kinase inhibitors High-throughput virtual screening Molecular dynamics simulation
暂未订购
HER-2突变晚期非小细胞肺癌的研究进展 被引量:1
9
作者 张良 杨长良 +1 位作者 李佩东 程颖 《肿瘤防治研究》 2025年第2期87-92,共6页
近年来,随着抗肿瘤药物研发在非小细胞肺癌(NSCLC)中的快速发展以及高通量测序技术在临床的广泛应用,人表皮生长因子受体-2(HER-2)基因作为NSCLC的一种罕见靶点逐渐引起重视并开展了一系列的探索性研究。传统的化疗以及免疫治疗在HER-2... 近年来,随着抗肿瘤药物研发在非小细胞肺癌(NSCLC)中的快速发展以及高通量测序技术在临床的广泛应用,人表皮生长因子受体-2(HER-2)基因作为NSCLC的一种罕见靶点逐渐引起重视并开展了一系列的探索性研究。传统的化疗以及免疫治疗在HER-2突变人群中疗效并不满意,而抗HER-2单克隆抗体和泛HER抑制剂对生存改善有限。抗体偶联药物(ADC)的发展让HER-2突变NSCLC迎来了转机,以德曲妥珠单抗为代表的新型ADC药物获得了突破,开创了HER-2突变晚期NSCLC精准治疗的新纪元。此外,新型HER-2抑制剂展现了令人鼓舞的初步疗效和安全性,研究正在如火如荼地开展。本文将围绕HER-2突变NSCLC的最新研究进展进行系统综述。 展开更多
关键词 非小细胞肺癌 her-2突变 抗体偶联药物 her-2抑制剂
暂未订购
吡咯替尼联合TCbH新辅助化疗方案对晚期HER-2阳性乳腺癌的近期疗效观察 被引量:1
10
作者 李静 朱九荣 王征 《实用癌症杂志》 2025年第4期646-649,共4页
目的探讨吡咯替尼联合TCbH新辅助化疗方案治疗晚期HER-2阳性乳腺癌的近期疗效。方法选取晚期HER-2阳性乳腺癌患者90例,随机数字表法分为对照组、观察组,每组各45例,对照组接受TCbH新辅助化疗方案,观察组接受吡咯替尼联合TCbH新辅助化疗... 目的探讨吡咯替尼联合TCbH新辅助化疗方案治疗晚期HER-2阳性乳腺癌的近期疗效。方法选取晚期HER-2阳性乳腺癌患者90例,随机数字表法分为对照组、观察组,每组各45例,对照组接受TCbH新辅助化疗方案,观察组接受吡咯替尼联合TCbH新辅助化疗方案,治疗4个周期后评估近期疗效,分别于治疗前、治疗4个周期后采用电化学发光免疫法检测CEA、CA153、TPS水平,应用流式细胞仪检测CD3^(+)、CD4^(+)、CD8^(+),并于治疗期间统计不良反应情况。结果两组近期疗效比较,P>0.05。观察组肿瘤标志物水平均低于对照组(P<0.05),CD3^(+)、CD4^(+)水平、腹泻、手足综合征发生率均高于对照组(P<0.05)。结论吡咯替尼联合TCbH新辅助化疗方案治疗晚期HER-2阳性乳腺癌疗效良好,但可能会引起腹泻和手足综合征等不良反应。 展开更多
关键词 晚期乳腺癌 her-2阳性 吡咯替尼
暂未订购
帕妥珠单抗联合新辅助化疗对HER-2阳性乳腺癌患者的临床疗效 被引量:1
11
作者 史磊 曹非 张帅 《河南医学研究》 2025年第7期1301-1304,共4页
目的分析帕妥珠单抗联合TCH新辅助化疗对HER-2阳性乳腺癌的疗效。方法选择2020年8月至2022年8月漯河市中心医院收治的140例HER-2阳性乳腺癌患者,按掷硬币法分为两组,各70例。对照组采取TCH新辅助化疗,观察组采取帕妥珠单抗联合TCH新辅... 目的分析帕妥珠单抗联合TCH新辅助化疗对HER-2阳性乳腺癌的疗效。方法选择2020年8月至2022年8月漯河市中心医院收治的140例HER-2阳性乳腺癌患者,按掷硬币法分为两组,各70例。对照组采取TCH新辅助化疗,观察组采取帕妥珠单抗联合TCH新辅助化疗,比较两组治疗结束时的临床疗效,治疗前、治疗6个疗程转化生长因子-β1(TGF-β1)、血管内皮生长因子(VEGF)指标,统计治疗期间不良反应发生率。结果治疗结束时,观察组总有效率高于对照组(P<0.05);治疗6个疗程后,两组TGF-β1、VEGF水平均低于治疗前,观察组低于对照组(P<0.05);住院期间两组不良反应发生率差异无统计学意义(P>0.05)。结论帕妥珠单抗联合TCH新辅助化疗可有效提高HER-2阳性乳腺癌患者疗效,降低TGF-β1、VEGF水平,减弱肿瘤细胞的转移性和扩散能力,未增加不良反应。 展开更多
关键词 乳腺癌 her-2阳性 新辅助化疗 帕妥珠单抗 疗效 不良反应
暂未订购
乳腺癌组织ZMYND10表达及其与ER、PR、HER-2的关系
12
作者 叶敏 张锦丰 +3 位作者 吴静娜 朱文标 杨日辉 范苑林 《中南医学科学杂志》 2025年第6期1061-1064,共4页
目的探究ZMYND10在乳腺癌组织中的表达水平及其与雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体-2(HER-2)表达的关系。方法选择乳腺癌患者148例,收集临床资料及肿瘤组织标本。采用免疫组织化学法检测ZMYND10在乳腺癌组织及癌旁... 目的探究ZMYND10在乳腺癌组织中的表达水平及其与雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体-2(HER-2)表达的关系。方法选择乳腺癌患者148例,收集临床资料及肿瘤组织标本。采用免疫组织化学法检测ZMYND10在乳腺癌组织及癌旁正常组织中的表达,根据ZMYND10表达水平将患者分为高表达组与低表达组,并检测两组ER、PR和HER-2表达情况,采用多因素Logistic回归分析ZMYND10表达与临床资料及各指标的关系。结果ZMYND10在乳腺癌组织中的阳性表达率低于癌旁正常组织(P<0.05)。高表达组中年龄<50岁及淋巴转移<4个者比例高于低表达组(P<0.05)。高表达组中PR阳性者比例高于低表达组(P<0.05)。回归分析显示,年龄<50岁及PR阳性均为ZMYND10高表达的影响因素(P<0.05)。结论ZMYND10在乳腺癌组织中低表达,其高表达与年龄<50岁及PR阳性有密切关系。 展开更多
关键词 乳腺癌 ZMYND10 ER PR her-2
暂未订购
安罗替尼在HER-2阴性晚期乳腺癌中的临床疗效研究进展
13
作者 王玉凤 冯乐霞 +4 位作者 党会芬 王千千 罗旭 吴淑潇 田迎霞 《现代肿瘤医学》 2025年第3期494-500,共7页
乳腺癌是女性最常见的恶性肿瘤,抗血管生成治疗是其重要的治疗手段之一。小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)安罗替尼作为抗血管生成药物中的一类,通过抗血管生成抑制肿瘤细胞生长。该文对安罗替尼在HER-2阴性晚期... 乳腺癌是女性最常见的恶性肿瘤,抗血管生成治疗是其重要的治疗手段之一。小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)安罗替尼作为抗血管生成药物中的一类,通过抗血管生成抑制肿瘤细胞生长。该文对安罗替尼在HER-2阴性晚期乳腺癌患者中的临床研究进展及真实世界中的应用作一综述。 展开更多
关键词 her-2阴性晚期乳腺癌 安罗替尼 抗血管生成治疗 临床疗效
暂未订购
免疫联合靶向和化疗一线治疗HER-2阳性胃癌的疗效及安全性
14
作者 张书培 杨磊 +3 位作者 张明军 李烦繁 杨震 杨扬 《安徽医专学报》 2025年第2期16-19,共4页
目的:探讨HER-2阳性晚期胃癌一线治疗中应用免疫治疗联合抗HER-2靶向治疗和化疗的疗效及安全性。方法:收集一线接受曲妥珠单抗联合化疗、联合/不联合PD-1/PD-L1抑制剂免疫治疗的85例HER-2阳性晚期胃癌患者的临床资料做回顾性分析,其中3... 目的:探讨HER-2阳性晚期胃癌一线治疗中应用免疫治疗联合抗HER-2靶向治疗和化疗的疗效及安全性。方法:收集一线接受曲妥珠单抗联合化疗、联合/不联合PD-1/PD-L1抑制剂免疫治疗的85例HER-2阳性晚期胃癌患者的临床资料做回顾性分析,其中36例患者接受免疫治疗联合曲妥珠单抗和化疗,49例患者接受曲妥珠单抗联合化疗。记录疗效、预后及治疗相关不良事件。结果:靶免联合化疗组患者的ORR、DCR略高于靶向联合化疗组,但差异均无统计学意义(P>0.05)。靶免联合化疗组患者中位PFS显著长于靶向联合化疗组(P<0.05)。两组患者治疗相关不良事件的发生率相当(P>0.05)。结论:HER-2阳性晚期胃癌一线治疗中,在曲妥珠单抗联合化疗的标准治疗方案中加入免疫治疗,可显著延长PFS,且安全性可控。 展开更多
关键词 晚期胃癌 her-2阳性 一线 免疫治疗 生存获益
暂未订购
HER-2阳性晚期胃癌多种序贯治疗方案的成本-效用分析
15
作者 刘娜娜 管欣 胡霞 《中国药房》 北大核心 2025年第13期1629-1634,共6页
目的从中国卫生体系的角度,评估不同序贯治疗方案治疗人表皮生长因子受体2(HER-2)阳性晚期胃癌的经济性。方法从ToGA、WJOG 4007和RAINBOW-Asia试验中获取生存数据,采用网状Meta分析进行调整。构建四状态Markov模型评估6种治疗序列的经... 目的从中国卫生体系的角度,评估不同序贯治疗方案治疗人表皮生长因子受体2(HER-2)阳性晚期胃癌的经济性。方法从ToGA、WJOG 4007和RAINBOW-Asia试验中获取生存数据,采用网状Meta分析进行调整。构建四状态Markov模型评估6种治疗序列的经济性,模拟时限为终身,循环周期为4周(28 d),模型的主要输出参数包括总成本、质量调整生命年(QALY)和增量成本-效果比(ICER)。通过敏感性分析检验基础分析结果的稳健性,并对曲妥珠单抗进行降价情境分析。结果相比化疗序贯紫杉醇,曲妥珠单抗联合化疗序贯紫杉醇或伊立替康或雷莫西尤单抗联合紫杉醇的ICER分别为349845.25、772410.64、2510470.39元/QALY,均超过3倍我国2023年人均国内生产总值(GDP)作为的意愿支付(WTP)阈值(268074元/QALY),显示化疗序贯紫杉醇方案为最优治疗方案。敏感性分析结果证明了基础分析结果的稳健性。情境分析结果表明,当曲妥珠单抗降价幅度大于20%时,在本研究的WTP阈值下,曲妥珠单抗联合化疗序贯紫杉醇方案开始具有经济性。结论在以3倍我国2023年人均GDP作为WTP阈值时,化疗序贯紫杉醇是治疗HER-2阳性晚期胃癌的最优方案,曲妥珠单抗联合化疗序贯紫杉醇为次优方案。随着医保政策优化力度的增大,曲妥珠单抗联合化疗序贯紫杉醇有望成为最具经济性的治疗方案。 展开更多
关键词 her-2阳性晚期胃癌 化疗 紫杉醇 曲妥珠单抗 序贯治疗 成本-效用分析 网状Meta分析 MARKOV模型
暂未订购
免疫组化Her-2与CA199、CA242对胃癌患者的诊断效能分析
16
作者 魏群 李颖 张艳萍 《中华养生保健》 2025年第6期63-66,共4页
目的探究免疫组化人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)与糖类蛋白抗原199(Carbohydrate antigen199,CA199)、糖类蛋白抗原CA242(Carbohydrate antigen242,CA242)对胃癌患者的诊断效能。方法选取2022... 目的探究免疫组化人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)与糖类蛋白抗原199(Carbohydrate antigen199,CA199)、糖类蛋白抗原CA242(Carbohydrate antigen242,CA242)对胃癌患者的诊断效能。方法选取2022年1月—2023年1月寿光市人民医院收治的106例疑似胃癌患者作为研究对象,完成血清学检测、免疫组化方法检测,比较不同分期胃癌患者HER-2表达、CA199及CA242水平,在此基础上以术后病理检查结果为金标准,比较单项检测指标与联合检测指标的诊断效能(诊断灵敏度、特异性、准确性等)差异。结果Ⅳ期、Ⅲ期胃癌患者Her-2阳性率85.0%(17/20)、68.0%(17/25),较Ⅰ期、Ⅱ期胃癌患者31.25%(10/32)、37.93%(11/29)高(P均<0.05)1。组内比较:Ⅱ期(45.31±5.21)U/mL、Ⅲ期(85.47±7.15)U/mL、Ⅳ期(123.35±9.21)U/mL胃癌患者CA199水平高于Ⅰ期(40.35±2.21)U/mL(P均<0.05),Ⅲ期、Ⅳ期胃癌患者CA199水平高于Ⅱ期(P均<0.05),Ⅳ期胃癌患者CA199水平高于Ⅲ期(P<0.05)。Ⅱ期(35.59±4.31)U/mL、Ⅲ期(76.25±6.03)U/mL、Ⅳ期(81.31±8.27)U/mL胃癌患者CA242水平高于Ⅰ期(30.31±2.25)U/mL(P均<0.05),Ⅲ期、Ⅳ期胃癌患者CA242水平高于Ⅱ期(P均<0.05),Ⅳ期胃癌患者CA242水平高于Ⅲ期(P<0.05)。经ROC曲线分析显示,联合检测AUC值0.903>Her-2、CA242、CA199(0.821、0.775、0.769),差异有统计学意义(P<0.05)。结论动态监测Her-2与CA199、CA242变化,及时判断胃癌患者病情发展,且联合检测指标诊断效果更理想,有助于提高疾病的诊断准确性、敏感度、特异度,为后续治疗方案的合理制定提供重要的参考依据。 展开更多
关键词 胃癌 免疫组化 her-2 CA199 CA242 诊断效能
暂未订购
血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌曲妥珠单抗敏感性的相关性
17
作者 陈柯 牛萍 王芳 《实用癌症杂志》 2025年第1期9-12,共4页
目的探讨血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌曲妥珠单抗敏感性的关系。方法选取Her-2阳性乳腺癌患者100例,均接受曲妥珠单抗治疗,根据RECIST1.1标准评价疗效,将CR+PR纳入敏感组,SD+PD纳入耐药组。同时期选取健康人群30名纳入对照... 目的探讨血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌曲妥珠单抗敏感性的关系。方法选取Her-2阳性乳腺癌患者100例,均接受曲妥珠单抗治疗,根据RECIST1.1标准评价疗效,将CR+PR纳入敏感组,SD+PD纳入耐药组。同时期选取健康人群30名纳入对照组。比较3组血清Her-2-ECD、TPS水平。分析Her-2-ECD、TPS水平与乳腺癌患者临床病理参数和疗效的关系。结果CR+PR共79例,SD+PD共21例。3组血清Her-2-ECD、TPS水平比较,差异有统计学意义(P<0.05),其中耐药组血清Her-2-ECD、TPS水平最高,敏感组次之,对照组最低。不同组织学分级、肿瘤转移部位数量患者血清Her-2-ECD、TPS水平比较,差异有统计学意义(P<0.05);不同年龄、月经状态、ECOG评分患者血清Her-2-ECD、TPS水平比较,差异无统计学意义(P>0.05)。血清Her-2-ECD、TPS水平联合预测靶向治疗疗效灵敏度84.69%、特异度78.49%、AUC 0.841,均较单一检测更高(P<0.05)。耐药组中血清Her-2-ECD>41.55 ng/ml、血清TPS>118.47 U/L的患者占比均高于敏感组(P<0.05)。结论血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌患者对曲妥珠单抗治疗的敏感性具有一定关系,联合检测可以提高对靶向治疗疗效的预测能力。 展开更多
关键词 乳腺癌 her-2阳性 her-2-ECD TPS 曲妥珠单抗 敏感性
暂未订购
能谱CT定量参数预测胃癌分化程度及HER-2表达的应用价值 被引量:1
18
作者 刘悦 张慧 +2 位作者 周清清 余玉盛 张宏 《放射学实践》 北大核心 2025年第6期725-731,共7页
目的:探讨能谱CT定量参数术前预测胃癌分化程度及HER-2表达的效能。方法:回顾性搜集南京市江宁医院2021年1月至2024年1月经病理确诊并行能谱CT扫描的50例胃癌患者资料,采用免疫组织化学染色法检测胃癌组织标本中HER-2蛋白的表达。测量能... 目的:探讨能谱CT定量参数术前预测胃癌分化程度及HER-2表达的效能。方法:回顾性搜集南京市江宁医院2021年1月至2024年1月经病理确诊并行能谱CT扫描的50例胃癌患者资料,采用免疫组织化学染色法检测胃癌组织标本中HER-2蛋白的表达。测量能谱CT动脉期及静脉期40、70、100 keV单能量图像中病灶的CT值(CT_(40keV)、CT_(70keV)、CT_(100keV))、碘浓度(IC)、有效原子序数(Z_(eff)),并计算归一化碘浓度(NIC)、归一化有效原子序数(NZ_(eff))、能谱曲线斜率(λHU)、动脉增强指数(AEF)、细胞外容积(ECV)。采用受试者工作特征(ROC)曲线及曲线下面积(AUC)、灵敏度、特异度分析能谱CT各定量参数对胃癌分化程度及HER-2表达状态的预测效能。结果:低分化组能谱CT动脉期参数CT_(40keV)、CT_(70keV)、CT_(100keV)、λHU、IC、NIC、Z_(eff)及ECV均高于中/高分化组,差异具有统计学意义(P<0.05)。其中ECV的单参数预测效能最佳,AUC为0.871,灵敏度75.9%,特异度95.0%。多参数联合的预测效能优于单参数,AUC为0.937,灵敏度86.7%,特异度95.0%(Delong,P<0.05)。HER-2阳性组能谱CT动脉期参数CT_(40keV)、CT_(70keV)、λHU、IC、NIC、Z_(eff)及静脉期参数λHU、IC、NIC、Z_(eff)均大于HER-2阴性组,差异具有统计学意义(P<0.05)。其中动脉期参数Z_(eff)的单参数预测效能最佳,AUC为0.784,灵敏度77.3%,特异度75.0%。多参数联合的预测效能优于单参数,AUC为0.858,灵敏度81.8%,特异度83.3%(Delong,P<0.05)。结论:能谱CT定量参数对胃癌组织分化程度及HER-2表达具有较好的预测效能,有望为患者术前个性化临床治疗的制定和预后提供一定的影像学依据。 展开更多
关键词 胃肿瘤 体层摄影术 X线计算机 her-2
暂未订购
Identification and molecular characterization of two novel mutations in COL1A2 in two Chinese families with osteogenesis imperfecta 被引量:3
19
作者 Zhenping Xu Yulei Li +5 位作者 Xiangyang Zhang Fanming Zeng Mingxiong Yuan Mugen Liu Qing Kenneth Wang Jing Yu Liu 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2011年第4期149-156,共8页
Osteogenesis imperfecta(OI,also known as brittle bone disease)is caused mostly by mutations in two type I collagen genes,COL1A1 and COLIA2 encoding the pro-α1(I)and pro-α2(I)chains of type I collagen,respectiv... Osteogenesis imperfecta(OI,also known as brittle bone disease)is caused mostly by mutations in two type I collagen genes,COL1A1 and COLIA2 encoding the pro-α1(I)and pro-α2(I)chains of type I collagen,respectively.Two Chinese families with autosomal dominant OI were identified and characterized.Linkage analysis revealed linkage of both families to COL1A2 on chromosome 7q21.3-q22.1.Mutational analysis was carried out using direct DNA sequence analysis.Two novel missense mutations,c.3350AG and c.3305GC,were identified in exon 49 of COL1A2 in the two families,respectively.The c.3305GC mutation resulted in substitution of a glycine residue(G)by an alanine residue(A)at codon 1102(p.G1102A),which was found to be mutated into serine(S),argine(R),aspartic acid(D),or valine(V)in other families.The c.3350AG variant may be a de novo mutation resulting in p.Y1117C.Both mutations co-segregated with OI in respective families,and were not found in 100 normal controls.The G1102 and Y1117 residues were evolutionarily highly conserved from zebrafish to humans.Mutational analysis did not identify any mutation in the COX-2 gene(a modifier gene of OI).This study identifies two novel mutations p.G1102A and p.Y1117C that cause OI,significantly expands the spectrum of COL1A2 mutations causing OI,and has a significant implication in prenatal diagnosis of OI. 展开更多
关键词 Osteogenesis imperfecta mutation COL1A2 COX-2
原文传递
信迪利单抗联合XELOX方案治疗Her-2阴性晚期胃癌的临床观察
20
作者 李雨濛 王宁 许建茹 《实用癌症杂志》 2025年第12期2016-2018,2023,共4页
目的探讨信迪利单抗联合XELOX方案治疗Her-2阴性晚期胃癌的临床效果及对患者肿瘤标志物、T淋巴细胞亚群及生活质量的影响。方法选取162例Her-2阴性晚期胃癌患者,按随机数字表法分2组,各81例。对照组行XELOX方案治疗,观察组加用信迪利单... 目的探讨信迪利单抗联合XELOX方案治疗Her-2阴性晚期胃癌的临床效果及对患者肿瘤标志物、T淋巴细胞亚群及生活质量的影响。方法选取162例Her-2阴性晚期胃癌患者,按随机数字表法分2组,各81例。对照组行XELOX方案治疗,观察组加用信迪利单抗治疗,2组均治疗3个周期。比较2组临床疗效、血清肿瘤标志物、T淋巴细胞亚群、生存质量及不良反应。结果观察组疾病控制率高于对照组(P<0.05)。治疗后观察组肿瘤标志物水平低于对照组(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)[(65.93±6.14)%、(39.58±3.83)%、(1.77±0.27)]高于对照组的[(58.85±5.83)%、(35.36±3.65)%、(1.43±0.24)],CD8^(+)[(22.31±2.12)%]低于对照组[(24.73±2.24)%],差异有统计学意义(P<0.05)。治疗后,观察组生存质量各项评分分别为(88.63±4.37)分、(86.74±5.32)分、(89.85±5.38)分、(90.58±4.14)分,均高于对照组的(80.15±5.85)分、(79.63±5.49)分、(82.55±5.43)分、(84.51±5.35)分,差异有统计学意义(P<0.05)。2组不良反应相比,差异无统计学意义(P>0.05)。结论信迪利单抗联合XELOX方案可控制Her-2阴性晚期胃癌的进展,降低肿瘤标志物水平,纠正免疫异常,且安全性尚可。 展开更多
关键词 her-2阴性 晚期胃癌 信迪利单抗 XELOX方案 肿瘤标志物 T淋巴细胞亚群
暂未订购
上一页 1 2 126 下一页 到第
使用帮助 返回顶部